Sanofi points to positive results for Sarilumab rheumatoid drug

PARIS, June 12 Thu Jun 12, 2014 1:14am EDT

PARIS, June 12 (Reuters) - French drug maker Sanofi and its partner Regeneron on Thursday said they had presented positive phase three results for their Sarilumab rheumatoid arthritis drug.

Sarilumab is an injectable antibody that works by blocking an inflammation-causing protein called interleukin 6. It is similar to Actemra, Roche's fast-growing treatment approved in 2010.

(Reporting by Astrid Wendlandt; editing by Blaise Robinson)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.